Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $46
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $39 to $46.
Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $39 to $46.